Dimezeft 2.5 Injection (Ceftazidime (2gm) + Avibactam (0.5gm))

What are the business opportunities for Ceftazidime 2g + Avibactam 0.5g Injection in the PCD pharma franchise market?

Ceftazidime 2g + Avibactam 0.5g Injection has strong demand in the critical care, infectious diseases, hospital care, and specialty anti-infective segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on advanced hospital injectables and institutional pharmaceutical portfolios.

Why should medical distributors include Ceftazidime 2g + Avibactam 0.5g Injection in their product range?

Medical distributors and agencies can benefit from consistent demand for management of serious multidrug-resistant (MDR) bacterial infections under specialist medical supervision. Ceftazidime 2g is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis and is active against a broad range of susceptible Gram-negative organisms Avibactam 0.5g is a beta-lactamase inhibitor that restores the activity of ceftazidime against certain beta-lactamase-producing bacteria, including many resistant Gram-negative pathogens This combination is commonly indicated for the treatment of complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (in combination with metronidazole), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and other serious infections caused by susceptible organisms, as advised by healthcare professionals and institutional antimicrobial stewardship guidelines Administered by intravenous infusion, with dosage individualized according to the patient's renal function, severity of infection, and microbiological findings Should be reserved for suspected or confirmed infections caused by susceptible organisms, particularly when resistant pathogens are involved, to support responsible antibiotic use and help minimize antimicrobial resistance Frequently utilized in intensive care units (ICUs), infectious disease departments, tertiary care hospitals, transplant centers, and emergency care settings Widely prescribed by infectious disease specialists, intensivists, nephrologists, pulmonologists, and general physicians managing severe bacterial infections This strengthens a comprehensive critical care and advanced anti-infective portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for Ceftazidime 2g + Avibactam 0.5g Injection?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Ceftazidime 2g + Avibactam 0.5g Injection with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from strong demand in tertiary care hospitals, critical care units, and institutional procurement, along with reliable supply chain support, repeat business, and attractive margins in the specialty injectable antibiotic segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, wholesalers, and institutional suppliers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality hospital injectable and anti-infective products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.